News Release

Dengue immunity may be protective against symptomatic Zika, study finds

Peer-Reviewed Publication

NIH/National Institute of Allergy and Infectious Diseases

Bite by an <i>Aedes</i> Mosquito

image: Bite by an Aedes mosquito. This species transmits dengue and Zika. view more 

Credit: NIAID


Children with a history of prior dengue virus infection had a significantly lower risk of being symptomatic when infected by Zika virus, according to a study in Nicaragua of more than 3,000 children aged 2 to 14 years. Experts have worried that prior dengue virus infection could exacerbate severe Zika disease. However, the new findings, published in PLOS Medicine, indicate that prior dengue immunity in children may in fact be protective against symptomatic Zika disease.

The research was conducted by investigators at the University of Michigan in Ann Arbor; the University of California, Berkeley; the Ministry of Health in Managua, Nicaragua; and the Sustainable Sciences Institute, also in Managua. The research was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

While dengue virus has been entrenched in the Americas for decades, Zika virus was not reported in the region until 2015. Zika virus and dengue virus are both transmitted by Aedes aegypti mosquitoes and cause similar symptoms, including fever, rash, and joint pain. In some cases, Zika virus infection can cause neurological issues, and infection during pregnancy can lead to birth defects and developmental problems in babies (a condition called congenital Zika syndrome). However, many people do not show symptoms when infected with either Zika virus or dengue virus.

It has been observed that in some epidemiological settings, a second dengue infection can be much more severe than a first dengue infection. Since dengue and Zika are closely related, it is important to know whether Zika following a dengue infection could also be more severe. To examine this potential relationship, the authors studied the 2016 epidemic of Zika in a longstanding cohort of children in Managua, many of whom had dengue infection histories.

Among the 3,893 children aged 2 to 14 years in the study, the authors estimate there were 1,356 Zika infections--560 of which were symptomatic cases--from January 2016 through February 2017. Case counts are based on infections confirmed by laboratory detection of Zika virus in the body using a method called RT-PCR (used to confirm symptomatic cases at the time of infection), and an algorithm developed to serologically classify--a process that involves examining antibodies in blood samples--cases not confirmed by RT-PCR (primarily clinically inapparent cases). Using data from the 15 years of the pediatric cohort, the investigators determined exposure histories for 3,027 of the children, of which 743 children had at least one dengue infection.

In statistical models adjusted for sex and age (younger children are less likely to have had dengue virus infection), children with a previous dengue virus infection before March 2015 had a significantly lower risk of symptomatic Zika virus infection. However, prior dengue virus infections did not affect the rate of total Zika virus infections, which includes both symptomatic and clinically inapparent cases.

These data indicate that prior dengue immunity in children may be protective against symptomatic Zika infection, according to the authors. They note that future research should investigate the immunological mechanisms of cross-protection between dengue virus and Zika virus and examine whether dengue immunity is protective against congenital Zika syndrome or Zika-related neurological complications.



A Gordon et al. Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. PLOS Medicine DOI: 10.1371/journal.pmed.1002726 (2019).


NIAID Director Anthony S. Fauci, M.D., is available for comment. Mark Challberg, Ph.D., flaviviruses program officer, Virology Branch in NIAID's Division of Microbiology and Infectious Diseases, is also available for comment.


To schedule interviews, please contact Jennifer Routh, (301) 402-1663,

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH...Turning Discovery Into Health®

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.